FDA-Approved Biosimilar Medications for Adult ADHD Management
This article covers FDA-approved biosimilar drugs for adult ADHD, including key medications like atomoxetine, Mydayis, and Cotempla XR-ODT. It emphasizes the importance of proper diagnosis and medical guidance for managing ADHD effectively in adults.
Sponsored
Attention deficit hyperactivity disorder (ADHD) affects the brain's development and functioning across all age groups. It is characterized by symptoms such as difficulty focusing, impulsivity, and hyperactivity, which can significantly impact daily life. For adults diagnosed with ADHD, several biosimilar drugs have received approval from the U.S. Food and Drug Administration (FDA) to help manage symptoms effectively.
Importance of Diagnosis
Many children display signs of ADHD, such as trouble paying attention or controlling behavior, which can be overlooked. When these symptoms persist into adulthood, proper diagnosis becomes essential for appropriate treatment.
FDA has authorized generic formulations like atomoxetine (Strattera) for both children and adults with ADHD.
Shire’s Mydayis (SHP465), containing amphetamine and dextroamphetamine, is approved for individuals over 12 years old, providing symptom relief for up to 16 hours.
Cotempla XR-ODT is designed for children and teens aged 6-17, featuring an easy-to-dissolve tablet that doesn’t require water.
These biosimilar medications are part of a comprehensive treatment plan including therapy. Always consult healthcare professionals before starting any medication to ensure safe and effective management of ADHD symptoms.
